Furthermore, studies have confirmed that both pirfenidone and nintedanib exert antifibrotic effects on macrophages and fibroblasts through the SPP1–AKT pathway, indicating that SPP1 is a potential target for IPF treatment [202]. The gene discussed is SPP1; the disease is idiopathic pulmonary fibrosis.